ZRANB1 and prostate cancer: In our previous study, we demonstrated that TRABID overexpression contributes to HR deficiency and sensitizes prostate cancer cells to synthetic lethality by PARP inhibitors11, indicating that protein posttranslational modifications are also important sources of HR deficiency.